Diego Medina-Castro

Dr. Diego Medina-Castro

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
Verified
Journal Article
Closed access
TSTzinnia Gabriela Soto-Bernal
Tzinnia Gabriela Soto-Bernal
ABAntonio Baltazar-Raigosa
Antonio Baltazar-Raigosa
DMDiego Medina-Castro
Diego Medina-Castro
HVHector Rene Vega-Carrillo
Hector Rene Vega-Carrillo

1 November 2016 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
PHPablo Luis Hernández-Adame
Pablo Luis Hernández-Adame
DMDiego Medina-Castro
Diego Medina-Castro
JRJohanna Lizbeth Rodriguez-Ibarra
Johanna Lizbeth Rodriguez-Ibarra
MSMiguel Angel Salas-Luevano
Miguel Angel Salas-Luevano
HVHector Rene Vega-Carrillo
Hector Rene Vega-Carrillo

1 September 2018 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
TSTzinnia Gabriela Soto-Bernal
Tzinnia Gabriela Soto-Bernal
ABAntonio Baltazar-Raigosa
Antonio Baltazar-Raigosa
DMDiego Medina-Castro
Diego Medina-Castro
HVHector Rene Vega-Carrillo
Hector Rene Vega-Carrillo

1 January 2022 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
DMDiego Medina-Castro
Diego Medina-Castro
HVHector Rene Vega-Carrillo
Hector Rene Vega-Carrillo
JGJuan Galicia-Aragón
Juan Galicia-Aragón
TSTzinnia Gabriela Soto-Bernal
Tzinnia Gabriela Soto-Bernal
ABAntonio Baltazar-Raigosa
Antonio Baltazar-Raigosa

1 October 2016 in Annals of Nuclear Energy
Verified
Journal Article
Closed access
DMDiego Medina-Castro
Diego Medina-Castro
PHPablo L. Hernández-Adame
Pablo L. Hernández-Adame
CLConsuelo Letechipía de León
Consuelo Letechipía de León
LSLaszlo Sajo-Bohus
Laszlo Sajo-Bohus
HVHector Rene Vega-Carrillo
Hector Rene Vega-Carrillo

10 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NINorma Ibañez
Norma Ibañez
RLRégulo López-Callejas
Régulo López-Callejas
VTVíctor Toral-Rizo
Víctor Toral-Rizo
BRBenjamin G Rodriguez-Mendez
Benjamin G Rodriguez-Mendez
Edith Lara-CarrilloEdith Lara-Carrillo
Edith Lara-Carrillo
DMDiego Medina-Castro
Diego Medina-Castro
Background/Objectives: Recurrent oral ulcers (ROUs) are a common condition that significantly impacts patients’ quality of life. This pilot study was conducted to evaluate the feasibility and preliminary results of using non-thermal plasma (NTP) compared to low-level laser therapy (LLLT) and placebo to treat these ulcers. Methods: A prospective, controlled, randomised, parallel-group pilot study was conducted using a convenience sample of 50 patients with ROUs. Patients were randomly assigned (2:2:1) to one of three groups: NTP (n = 20), LLLT (n = 20), and placebo (n = 10). Feasibility and preliminary data acquisition were the primary goals. Exploratory outcomes included ulcer size reduction and safety profile. This was a single-blinded trial, where participants and outcome assessors were masked to group assignment. Ulcer size, pain perception, and time to complete healing were measured. For statistical analysis, ANOVA was used, with a p-value ≤ 0.05. Results: The groups were comparable at baseline. Exploratory results suggest that NTP demonstrated a promising trend in accelerating healing, with a mean healing time difference of 5.5 days compared to LLLT (2.5 ± 1.9 days vs. 8.0 ± 4.3 days) and 7.1 days compared to placebo (2.5 ± 1.9 days vs. 9.6 ± 5.3 days) (p < 0.001). Regarding pain, NTP provided significant and sustained relief. Patients in the NTP group were asymptomatic on day 2, unlike the LLLT and placebo groups, where pain persisted significantly (NTP VAS score at 1 h: 1.1 ± 2.1 vs. LLLT/Placebo VAS score at 1 h: 3.4 ± 2.4 and 7.3 ± 1.9, respectively) (p < 0.001). NTP was well tolerated, and no adverse events were reported. Conclusions: This pilot study suggests that NTP is a potentially safe and effective therapy for recurrent oral ulcers. Preliminary results indicate that it may accelerate healing and offer superior pain relief, warranting a large-scale clinical trial to confirm these findings.